Will Sanofi’s Dengvaxia Woes Spiral Beyond The Philippines?

Sanofi appears to be under mounting pressure in the Philippines over deaths allegedly linked to its dengue vaccine and after declining to refund costs of the doses already used in the Southeast Asian nation’s vaccination plan. Whether or not the goings on could have a domino effect could be crucial for the product’s future.

Vaccine
SANOFI IS UNDER FIRE IN THE PHILIPPINES OVER DENGVAXIA

Sanofi finds itself in the midst of a snowballing crisis in the Philippines over its dengue vaccine, Dengvaxia, after the Southeast Asian country said that the product may be related to some deaths. But the French multinational has declined to refund Manila the amount spent on its public dengue vaccination program and turned down a request for an indemnification fund.

Things appear to have escalated sharply after the Philippines said that an expert panel formed to probe if Dengvaxia was...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip